Describe the risk factors and discuss the management of multidrug-resistant (MDR) bacteria responsible for pneumonia among critically ill patients, including methicillin-resistant Staphylococcus aureus, extended spectrum beta-lactamase-producing Enterobactericeae, carbapenem-resistant Enterobactericeae, multidrug resistant Pseudomonas aeruginosa, and Acinetobacter baumannii.
INTRODUCTION
Hospital-acquired pneumonia (HAP) and ventilatorassociated pneumonia (VAP) represent a major problem in patients hospitalized in ICU, accounting for up to 20% of all health care-associated infections [1 && ,2]. Overall, the incidence of HAP ranges from 5 to 20 cases per 1000 hospital admissions, and approximately one-third of cases are represented by VAP [1 && ]. HAP and VAP are associated with high mortality rates (over 50%), with a dramatic impact on length of ICU stay and overall health care costs [3] . In this scenario, the dramatic increase of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria [4] have complicated management, therapy, and outcome of ICU-acquired pneumonia [5] . Potential MDR pathogens include: P. aeruginosa, Acinetobacter spp., extended spectrum beta-lactamase (ESBL)-producing, and carbapenem-resistant Enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus
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& ]. Specific risk factors for development of pneumonia caused by these pathogens have been recognized in ICU patients [9] . However, limited data regarding the optimal antimicrobial regimen for the treatment of HAP/VAP because of MDR/XDR/PDR pathogens are available. Carbapenems play a starring role, also when the isolate displays a resistant phenotype, and attention must be paid to dose, modality of administration (extended infusion), and plasma drug levels [10] . Colistin and aminoglycosides represent a possible therapeutic option, also if it is reported a poor lung penetration. Linezolid is considered the main option for MRSA, considering difficult to reach adequate serum concentrations for vancomycin, especially in septic patients. Finally, the use of aerosolized preparations has been recently proposed, but the optimal use in clinical practice has not been fully established so far. New promising antimicrobial agents for the treatment of MDR Pseudomonas aeruginosa and CRE infections have been recently approved, like ceftazidime/avibactam, ceftolozane/ tazobactam, meropenem/vaborbactam and plazomycin, or are in development (like imipenem/ relebactam) [11,12 && ,13 & ]. In this review, we will describe the current global epidemiology of MDR/ XDR/PDR strains, suggesting a possible strategy for risk stratification for empiric antibiotic treatment of HAP and VAP, in which involvement of these pathogens is suspected or confirmed, focusing on the role of both old and new antimicrobial agents. 
RISK FACTORS FOR ACQUISITION OF RESISTANT PATHOGENS

KEY POINTS
HAP/VAP because of multidrug-resistant (MDR) bacteria (e.g. methicillin-resistant Staphylococcus aureus, extended spectrum beta-lactamase-producing Enterobactericeae, carbapenem-resistant Enterobactericeae, multidrug-resistant Pseudomonas aeruginosai, and Acinetobacter baumannii) are burdened by high mortality rates in critically ill patients.
Mechanical ventilation, colonization with resistant pathogens, and use of broad-spectrum antibiotics are among the main risk factors associated with pneumonia caused by MDR bacteria.
Knowledge of the local epidemiology, patient risk stratification, prompt use of appropriate antimicrobial therapy, and implementation of antimicrobial stewardship protocols are key for the management of MDR infections in the ICU.
Combination therapy and novel molecules have been used for the treatment of severe infections caused by resistant bacteria, although large real-world studies are awaited to better define optimal treatment protocols. 16, 17] . Mechanical ventilation for more than 7 days and the presence of tracheostomy have also demonstrated to be specific for VAP [18] . Other factors that probably increase likelihood of MRSA pneumonia include prior known MRSA colonization detected via nasal or respiratory cultures or nonculture screening [19] . In previous studies in ICU patients, MRSA nasal colonization was found to be a poor predictor of the subsequent occurrence of MRSA lower respiratory tract infections requiring antibiotic treatment [20] , but with high negative-predictive value [21] . In addition, ICU pneumonia because of MRSA has been associated with late onset development and several variables reflecting mainly patient characteristics, including old age (>65 years), higher APACHE II score, use of corticoid, and pleural effusion [9, 17, 22, 23] . Although rare, vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA), either de novo or emergent have been described after exposure to glycopeptide therapy.
Extended spectrum beta-lactamaseproducing Enterobacteriaceae
The gastrointestinal tract is the main reservoir for ESBL-producing Enterobacteriaceae, and colonization with such organisms is a strong risk factor for subsequent infection [24, 25] . In many ICUs, screening for ESBL carriers is routinely performed. Barbier et al. found that among 594 ESBL carriers in ICU, 98 (16.4%) developed 118 ESBL infections, including 43 cases of pneumonia (36.5%). A 6-year prospective study performed in ICU found that among carriers, 13% patients developed ICU-acquired pneumonia of whom 43% had ESBL-pneumonia (6% of carriers). Multivariate analysis identified SAPS II at admission more than 43 and colonization with Enterobacter spp. or Klebsiella pneumoniae as independent predictive factors for ESBL pneumonia in patients with colonization [26] . The risk of infection with ESBLproducing organisms has also been described to rose in parallel with ICU length of stay, previous use of antibiotics (both as therapy and as prophylaxis), and age [25, 27, 28] . To assess the risk of CRE infection among carriers, a risk score (GRS, Giannella risk score) has been proposed, which includes admission to ICU (two points), invasive abdominal procedures (three points), chemotherapy/radiation therapy (four points), and rectal colonization (five points per each additional site) [35] . GRS has been validated in an external cohort of CRE colonized patients as a predictor not only for bacteraemia but also for other active CRE infections (including pneumonia), assessing at least 7 cut off points for the risk for CRE infection [36 && ].
Carbapenem-resistant Enterobacteriaceae
Multi-drug resistant Pseudomonas aeruginosa
Risk factors for the development of P. aeruginosa VAP have been related to baseline conditions of the patient and to nosocomial factors. Among baseline characteristics, the presence of lung disease (chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis) a high number of comorbidities (diabetes mellitus, renal failure), older age, solid cancer, and shock have been associated with the development of MDR P. aeruginosa ICU pneumonia [37, 38] . Among nosocomial factors, mechanical ventilation, prior P. aeruginosa colonization, admission to a ICU ward with high incidence of P. aeruginosa infections, a long hospitalization before ICU admission, and prolonged duration of ICU stay have been linked to MDR P. aeruginosa ICU respiratory infections [37] [38] [39] . One of the main concerns in the acquisition of resistance is previous antibiotic exposure. Several studies have reported that the emergence of MDR P. aeruginosa occurs after exposure to antipseudomonal antibiotics (mainly quinolones and carbapenems) [37, 40] . In contrast, another study performed in critically ill patients with active surveillance to detect the colonization of P. aeruginosa found that quinolones and antipseudomonal cephalosporins could prevent the acquisition of P. aeruginosa and that the use of these agents was not associated with the acquisition of resistance [41] .
Multi-drug resistant Acinetobacter baumannii
A. baumannii represents an important cause of nosocomial infections, especially among hospitalized patients in the ICU [42] . Most common A. baumannii infections in critically ill patients include VAP, bloodstream infections (BSI), complicated urinary tract infections (cUTI), and wound infections [43 && 
].
A. baumannii main characteristics are a remarkable capability of environmental persistence and the rapid spread across wards [42] . Furthermore, A. baumannii is not only intrinsically resistant to multiple antimicrobials but also prone to acquire new resistance determinants through a variety of different mechanisms [42, 44] . Immunosuppressed, elderly, debilitated, and critically ill patients are at increased risk for developing life-threatening A. baumannii infections [43 && ]. Multiple risk factors for acquisition of A. baumannii, including MDR species, have been described and include previous antimicrobial therapy (e.g. use of carbapenems and third-generation cephalosporins), prior colonization with A. baumannii, immunosuppression, and use of multiple invasive procedures (e.g. nasogastric tube, central venous, or urinary catheterization) [45] [46] [47] [48] [49] [50] . Among patients in the ICU, mechanical ventilation, respiratory failure at admission, previous sepsis during admission, and prolonged hospitalization have been associated with MDR A. baumannii infections [46] . Specifically, prior A. baumannii colonization appeared as a key independent risk factor for infection development [47] . Therefore, severe infections developing in critically ill patients with known A. baumannii colonizationor among patients in endemic areas or during hospital outbreaks -should be empirically treated with antimicrobials that cover MDR A. baumannii, possibly considering the pathogen's susceptibility profile [51] . Similar to other Gram-negative bacteria, the occurrence of carbapenem-resistance significantly hampers the choice of an effective antimicrobial treatment. The lack of randomized clinical trials limits the availability of specific guidelines on the treatment of A. baumannii. Recently, expert-based recommendations have been published aiming at identifying the main principles for the management of A. baumannii infections [51] .
MANAGEMENT OF PNEUMONIA BECAUSE OF MULTIDRUG-RESISTANT/EXTENSIVELY DRUG-RESISTANT/PANDRUG-RESISTANT PATHOGENS IN ICU PATIENTS
The choice of an adequate antibiotic regimen for treatment of infections because of MDR/XDR/PDR strains is challenging for physicians [52] . As a matter of fact, no large multicenter trials have evaluated the real effectiveness and safety of common antibiotic regimens used in clinical practice for treatment of MDR infections [53] . In a recent trial [54 && ] the superiority of combination therapy with colistin with meropenem versus colistin alone has been investigated. No differences in term of outcome in patients treated with combination compared with monotherapy in infections because of carbapenemresistant pathogens has been demonstrated, especially for Acinetobacter spp., including BSI, VAP, and/or HAP. However, superiority of combination therapy with monotherapy has been confirmed in several retrospective studies [55] [56] [57] . Of interest, these studies confirmed the utility of a meropenem-based regimen in the treatment of these infections, although punctual carbapenem MIC remained crucial for including or not meropenem in the combination regimens, particularly for CRE [58] .
A proposed algorithm for management of antibiotic therapy in patients with suspected HAP/VAP because of MDR/XDR/PDR pathogens is reported in Fig. 1 . Empirical antimicrobial therapy should be promptly started in patients with high probability of HAP/VAP especially in patients developing sepsis or septic shock, because delayed and inadequate treatments have been associated with increased morbidity and mortality [59] . Beta-lactam antibiotics alone or as part of a combination regimen are the backbone of empirical antibiotic regimen [1 && ], but different antibiotic combinations including aminoglyocoside, colistin, tigecycline, or trimethoprim-sulfamethoxazole are reported in literature [60, 61 && ]. As a matter of fact, antimicrobials used in the empirical regimens should be chosen based on local epidemiology and susceptibility [62] . The current approach is based on combination regimens containing two or three active drugs, especially for carbapenem-containing regimens, which have demonstrated significant advantages over monotherapies in terms of survival particularly for CRE FIGURE 1. Proposed algorithm for management of antibiotic therapy in patients with suspected hospital-acquired pneumonia/ ventilator-associated pneumonia because of multidrug-resistant/ extensively drug-resistant/pandrug-resistant pathogens. CRE, carbapenemase-producing Enterobacteriaceae; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; MDR, multidrug-resistant; MRSA, methicillin-resistant Staphylococcus aureus; PCT, procalcitonin; PDR, pandrug-resistant; VAP, ventilator-associated pneumonia; XDR, extensively drug-resistant. 
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infections [56] . Ceftazidime-avibactam should be considered as one of preferred option for empirical treatment of suspected HAP/VAP because of MDR pathogens focusing on CRE, in association with fosfomycin or gentamicin [63] . Recent data from Tumbarello et al. confirmed that ceftazidimeavibactam is a promising drug for treatment of severe CRE infections. Finally, meropenem/vaborbactam and imipenem/relebactam should be considered as future valid option for treatment of CRE infections [9] . Recent data from MERINO trial reported superiority of a monotherapy with meropenem compared with piperacillin/tazobactam in BSI caused by ceftriaxone-resistant K. pneumoniae and Escherichia coli [64] . These data confirm superiority of meropenem in the treatment of severe ESBL infections; however, considering a carbapenem-sparing strategy ceftolozane-tazobactam may be considered a valid alterative option for treatment of severe [66] [67] [68] . Durante-Mangoni et al. [69] showed that, in patients with MDR A. baumannii infections, mortality at 30 days was not reduced by the combination with rifampicin, however, microbiological eradication was higher for the combination. Other in-vitro studies explored the synergism of several combinations, suggesting that the combination of polymyxins and carbapenem are highly synergistic [70, 71] . On this basis, the combination of a carbapenem with colistin or colistin with rifampin seem to be the first options for the treatment of MDR A. baumannii infections [72] . Colistin aerosol inhalation therapy should be considered in ICUpneumonia because of MDR A. baumannii (Fig. 1 ) [67] [68] [69] . The initial therapy for ICU-acquired pneumonia because of P. aeruginosa should be based on combination of two antipseudomonal antibiotics from different classes, especially when patients are hospitalized in units where more than 20% of Gramnegative isolates are resistant to one of the backbone agents considered for monotherapy, like batalactams. Ceftolozane/tazobactam has proven to have a potent in-vitro activity against majority of MDR P. aeruginosa strains. Aminoglycosides should not be used as monotherapy and they show low lung penetration. Aerosol therapy may be considered only as adjunctive to intravenous therapy in selected cases of infections because of MDR strains. Moreover, the clinical efficacy of intravenous ceftobiprole for treatment of adult patients with HAP (excluded VAP) has been evaluated [73] . Ceftobiprole should be considered as a possible option for documented or suspected MRSA pneumonia, excluding VAP (see Fig. 1 ). Systematic empirical coverage of MRSA in ICU patients is object of debate. Vancomycin has been considered the treatment of choice for MRSA pneumonia [74] , however, several studies observed high rate of treatment failure and mortality [75] . Lung infection has been identified as an independent predictor of treatment failure in MRSA bacteremia treated with vancomycin [76, 77] , reflecting the poor penetration of this antibiotic into the lung tissue [78] . Linezolid showed a better pharmacological profile than vancomycin with better lung penetration [79] and was associated with significantly better clinical cure than vancomycin in treatment of patients with MRSA VAP [80, 81] .
Of importance, some authors analysed the impact of aerosolized antibiotics routinely used as initial empirical therapy for HAP/VAP [82] . Nebulized antibiotic should be added to empirical intravenous only in selected cases [83] . Theoretical benefits of local delivery include increased antibiotic concentration at the site of infection and low systemic absorption leading to decreased adverse effects and superinfections. The recent Infectious Diseases Society of America (IDSA) guidelines [1 && ] recommend using nebulized antimicrobial agents and systemic antibiotics, rather than systemic antibiotics alone, particularly in pulmonary infections caused by CRE. Available formulations for nebulization include gentamicin, amikacin, tobramycin, aztreonam, and colistin (see Fig. 1 ).
CONCLUSION
Various risk factors have been associated with isolation of resistant bacteria that are involved in HAP/ VAP in the ICU. Knowledge of the local resistant patterns and patient's risk stratification are important to assure an appropriate antimicrobial empiric therapy for severe infections. Although newly approved antibiotics and molecules still under development appear promising in clinical trials against resistant bacteria that cause HAP and VAP, results from real-world studies are often lacking, and conflicting results have emerged. Therefore, an optimal therapy for a vast number of MDR and XDR bacteria is still not well established. In this scenario, factors including the implementation of antimicrobial stewardship protocols, staff education (e.g. promotion of hand hygiene, environmental cleaning), strict isolation precautions, and targeted active microbiology surveillance programs remain crucial, particularly in areas that are endemic for MDR infections.
